Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.

Trial Profile

Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2011

At a glance

  • Drugs Antibacterials; Meropenem
  • Indications Bacterial infections; Systemic inflammatory response syndrome
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top